|Articles|December 14, 2022
PHASTAR Joins Oncology Development Program (ODP2)
Targeted program aims to identify and accelerate novel oncology innovations into commercially-attractive assets.
Advertisement
PHASTAR, has joined Lean Life Science’s Oncology Development Program (ODP2). The targeted program aims to identify and accelerate novel oncology innovations into commercially-attractive assets by offering support to academics and early-stage companies.
Read more about the program
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
BostonGene Expands AI-Driven Oncology Collaborations with New AstraZeneca Deal
2
Nipocalimab Delivers Positive Phase IIb Results in JASMINE SLE Trial
3
Securing Comparator Drugs in Competitive EU Markets: Challenges and Practical Solutions
4
ACT Brief: Rethinking Representation in Cancer Trials, Positive Phase IIb SLE Data, and a Major Obesity Drug Partnership
5